NEW YORK (
CHANGE IN RATINGS
initiated at Citi with a Buy rating and $15 price target. Several upcoming catalysts for the company's lead product, lluvien.
initiated at Credit Suisse with an Outperform rating and $16 price target. Alimera's healthcare products can achieve high margins and rapid profitability.
rated new Hold at ThinkEquity. Valuation call, as earnings tailwinds could moderate in the coming quarters.
downgraded at Goldman from Neutral to Sell. $20 price target. Company is facing currency headwinds and is facing a year of strategic transition.
rated new Buy at ThinkEquity. Management has positioned the company well, with lower price points.
rated new Buy at Sterne Agee. $14 price target. Touch handset sales should drive growth.
upgraded at Morgan Joseph from Hold to Buy. Company seeing higher demand from domestic row farmers and in Brazil.
initiated at Barclays with an Overweight rating and $15 price target. The shopping center REIT is well positioned to take advantage of significant buying opportunities over next several years.
Great Atlantic & Pacific Tea
initiated at Citi with a Hold rating and $6 price target. There could be significant upside if turnaround initiatives begin.
upgraded at Jefferies from Hold to Buy. Company has a strong pipeline and should benefit from currency volatility.
downgraded at Wells to Market Perform. Estimates raised, but the stock is already pricing in near-term growth.
upgraded at UBS from Neutral to Buy. $19 price target. Stock is down 30% over the past two months and appears attractively valued at less than 9 times earnings.
upgraded at Goldman from Neutral to Buy. $61 price target. Estimates also raised, as higher mining production should continue to boost CapEx rates.
(JMP - Get Report)
upgraded at UBS from Neutral to Buy. $50 price target. Company has a solid footing and the potential to generate above-average earnings growth.